Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and 'Ibogaine Exceptionalism'

FDA psychedelic approvals are framed as being on track despite ongoing chaos inside federal agencies and friction across parts of the psychedelics advocacy community. The dispatch also highlights how an election year can chill broader psychedelic policy reforms even while stakeholders expect it should not derail FDA’s review of specific psychedelic candidates. A major thread is ibogaine advocacy gaining momentum and becoming its own focused policy and lobbying realm, including what the author calls the promise and peril of this emerging push. The piece adds regional color on Texas, where ambition collides with bureaucracy, underscoring how state level developments and federal process both shape the real-world pace of approvals.